Life Technologies Corp. has finalized license agreements with several companies to provide rights to its CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines. The program is part of the company’s new out-licensing strategy, which also includes providing its product and technology portfolio to offer more customized solutions for OEM and other commercial use customers.

New licensees include: Advanced BioScience Laboratories, Inc., CNA Development LLC, Chong Kun Dang Pharmaceutical Corp., DiNonA Inc. of Korea, RecipharmCobra Biologics, Ltd. of the UK, evitria SA of Switzerland, Fusion Antibodies of Northern Ireland, Indian Immunologicals Limited of Hyderabad, India, among other others.

According to the company, its CHO lines are optimized for growth in suspension in the company’s chemically defined GIBCO media, permitting protein manufacturers to obtain good yields while reducing serum-associated risks. They have also been shown to be free of standard pathogens, making them well suited for therapeutic manufacturing.

Detailed cell line history documentation packages suitable for submission to the FDA as part of IND filings are provided to licensees, eliminating the need for preliminary testing.